Basic Company Data Data as of: April 3, 2011 Current Price $79.

90
Symbol PRGO PERRIGO CO H&C Composite Score
Description Perrigo Company is a global healthcare supplier that develops, manufactures and
Strong Buy
distributes OTC and generic prescription pharmaceuticals, infant formulas,
nutritional products, active pharmaceutical ingredients and pharmaceutical and
medical diagnostic products. The Company's primary markets and locations of
8.3
manufacturing and logistics operations are the US, UK, Mexico, and Australia.

Sector Health Care

Industry Pharmaceuticals, Biotechnology 0 1 2 3 4 5
Last Report Date 2/1/2011 Technical Score Fundamental Score
Earnings Date 4/29/2011 IPO Date 12/17/1991
Fundamentals Technicals
Market Cap. $7.5 B BETA 0.47 Price $79.90 MACD Trend Up
Price/Earnings 24.74 1Yr. EPS Growth Rate % 49.74% 50-Day MA $74.80 Stochastics Trend Down
Forward Price/Earnings 18.31 5Yr. Avg. EPS Growth Rate % 34.10% 200-Day MA $65.08 RSI Signal Trend Up
Price/Book 5.65 EPS Growth QoQ 27.63% 50/200 Day MA $9.72 S/T Trend Up
Forward PEG Ratio 1.44 Revenue Growth QoQ 33.29% Volume Pressure 1.45 L/T Trend Up
Return on Equity 36.92 Dividend Yield 0.35% Average Daily Volume 691,435 Bull / Bear Bull Trend
LT Debt/Equity 86.03% Cash Flow Per Share 3.44 M-Score (0 - 100%) 74%
H&C Fundamental Score 5.0 H&C Technical Score 3.3
Ownership Data
Inst. Buy/Sell Ratio 1.49 Management Ownership 8.39% 50 Day Moving Average S/T Support L/T Support
% Change of Insider Holdings -4.22% Short Interest Ratio 4.30 20 Day Moving Average S/T Resistance L/T Resistance

PERRIGO CO $82
$81
$80
$79
$78
$77
$76
$75
$74
$73
$72
$71
$70
$69
$68
$67
$66
$65
$64
$63
$62
$61
$60

10.0
Bull Trend Bear Trend

0.0

-10.0
2.0
Up / Down Volume Ratio
1.5
1.0
0.5
0.0
40

20

0
7-Dec-10 21-Dec-10 5-Jan-11 20-Jan-11 3-Feb-11 17-Feb-11 4-Mar-11 18-Mar-11 1-Apr-11
Volume x100,000
Fundamentals
PERRIGO CO
1
Earnings Per Share 2 Reported Estimate Target Price 19 Reported Estimate
$1.20 $90

$80
$1.00
$70

$0.80 $60

$50
$0.60
$40

$0.40 $30

$20
$0.20
$10

$0.00 $0

Total Revenues 1
Reported Estimate
Ownership EPS & Revenue Growth
Investment Advisor 79.54% Quarter EPS Growth Rev. Growth
$900
Individual 10.24% FQ3 2009 6% 5%
$800 Hedge Fund Manager 4.73% FQ4 2009 2% 18%
Pension Fund (ERISA) 2.94% FQ1 2010 55% 16%
$700 Mutual Fund Manager 1.39% FQ2 2010 48% 8%
Insurance Company 0.88% FQ3 2010 52% 6%
$600
Bank 0.24% FQ4 2010 45% 22%
$500 Unclassified 0.05% FQ1 2011 22% 21%
FQ2 2011 43% 23%
$400
Top Holders and % Outstanding Forward Growth Estimates
$300 FIDELITY MANAGEMENT 8.17% Quarter EPS Growth Rev. Growth
$200 ARKIN MOSHE 6.44% FQ3 2011 27% 28%
DELAWARE MANAGEMENT 4.58% FQ4 2011 39% 13%
$100 VANGUARD GROUP INC 4.02% FQ1 2012 29% 12%
WELLINGTON MANAGEMEN 3.43% FQ2 2012 17% 8%
$0
BLACKROCK FUND ADVIS 2.52%
STATE STREET CORP 2.42%
BLACKROCK INSTITUTIO 2.15%

Largest Geographic Segmentation of Revenue Product Segmentation of Revenue

Yearly Yearly
Segment Name FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 Segment Name FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
United States #N/A N/A #N/A N/A 1,244.96 969.32 #N/A N/A Consumer Healthcare $1,833.02 $1,638.77 $1,336.14 $1,037.31 $994.23
Outside the U.S #N/A N/A #N/A N/A 577.17 478.10 #N/A N/A RX Pharmaceuticals $237.65 $164.16 $161.27 $137.80 $120.94
API $139.29 $136.00 $149.55 $122.14 $110.71
Other $58.91 $67.93 $175.17 $150.18 $140.94

Disclosure: This material is provided for information only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. This material is not a complete analysis of all material facts respecting any issuer, industry
or security or of your investment objectives, parameters, needs or financial situation, and therefore is not a sufficient basis alone on which to base an investment decision. Horowitz & Company clients may hold positions (long or short) in investments discussed. Please click for
detailed disclosures and additional information about our stock ratings and scoring.

4/3/2011